Home » Stocks » PULM

Pulmatrix, Inc. (PULM)

Stock Price: $1.67 USD -0.02 (-0.89%)
Updated Mar 2, 2021 3:16 PM EST - Market open
Market Cap 87.24M
Revenue (ttm) 12.32M
Net Income (ttm) -20.45M
Shares Out 33.92M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $1.67
Previous Close $1.68
Change ($) -0.02
Change (%) -0.89%
Day's Open 1.65
Day's Range 1.61 - 1.72
Day's Volume 2,160,241
52-Week Range 0.90 - 3.04


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 5 months ago

LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non...

PRNewsWire - 6 months ago

LEXINGTON, Mass., Aug. 7, 2020 /PRNewswire/ -- Pulmatrix, Inc.

Zacks Investment Research - 7 months ago

Pulmatrix (PULM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

PRNewsWire - 8 months ago

LEXINGTON, Mass., June 26, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-...

Zacks Investment Research - 1 year ago

January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.

Other stocks mentioned: CODX, JNJ, TRIL, VXRT
Market Watch - 1 year ago

Shares of Pulmatrix Inc. more than doubled Monday, rocketing 124% on heavy volume, after the company said it entered into a "binding term sheet" with Cipla Ltd.

About PULM

Pulmatrix, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease... [Read more...]

Teofilo Raad
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, Pulmatrix's revenue was $7.91 million, an increase of 5,069.93% compared to the previous year's $153,000. Losses were -$20.60 million, 0.16% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Pulmatrix stock is "Buy" and the 12-month stock price forecast is 10.00.

Price Target
Analyst Consensus: Buy